Recentin headed to phase III in first-line colon ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 3
Volume 17
Issue 3

Based on Independent Data Monitoring Committee review of three phase II trials, AstraZeneca’s HORIZON III phase II/III study of its antiangiogenesis agent Recentin will progress directly into phase III. The study is a head-to-head comparison of first-line Recentin (cediranib, AZD2171) plus FOXFOX vs bevacizumab (Avastin) plus FOLFOX in patients with metastatic colorectal cancer

Based on Independent Data Monitoring Committee review of three phase II trials, AstraZeneca’s HORIZON III phase II/III study of its antiangiogenesis agent Recentin will progress directly into phase III. The study is a head-to-head comparison of first-line Recentin (cediranib, AZD2171) plus FOXFOX vs bevacizumab (Avastin) plus FOLFOX in patients with metastatic colorectal cancer.

Recentin is a highly potent and selective VEGF signaling inhibitor that inhibits all three VEGF receptors, particularly VEGFR-2, the predominant receptor through which VEGF exerts its effects on angiogenesis, the company said in a press release. The dose for the phase III trial is 20 mg/d orally.

The company further announced that the BR24 phase II/III study of Recentin at 30 mg/d in first-line non-small-cell lung cancer will not continue into phase III, based on phase II data analysis.

Although evidence of clinical activity was seen, there appeared to be an imbalance in toxicity, the company said. BR24 was being conducted by the National Cancer Institute of Canada Clinial Trials Group. 

Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content